A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

NCT00603941 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
19
Enrollment
INDUSTRY
Sponsor class

Stopped Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated dose could not be established

Conditions

Interventions

Sponsor

Daiichi Sankyo